APA (7th ed.) Citation

AR, K., A, J., M, B., C, K., A, S., M, A., . . . SL, P. (2026). Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): A multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial. The lancet. HIV, 13(6), e367. https://doi.org/10.1016/S2352-3018(25)00326-1

Chicago Style (17th ed.) Citation

AR, Kekitiinwa, et al. "Efficacy and Safety of Short-cycle, Dolutegravir-based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Multicentre, Open-label, Randomised, Parallel, Two-arm, Non-inferiority Trial." The Lancet. HIV 13, no. 6 (2026): e367. https://doi.org/10.1016/S2352-3018(25)00326-1.

MLA (9th ed.) Citation

AR, Kekitiinwa, et al. "Efficacy and Safety of Short-cycle, Dolutegravir-based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Multicentre, Open-label, Randomised, Parallel, Two-arm, Non-inferiority Trial." The Lancet. HIV, vol. 13, no. 6, 2026, p. e367, https://doi.org/10.1016/S2352-3018(25)00326-1.